Literature DB >> 8700366

Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function.

G M Frascà, M Martello, E Sestigiani, C Canova, A Vangelista, V Bonomini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8700366     DOI： 10.1093/oxfordjournals.ndt.a027280

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  4 in total

Review 1.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

2.  Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Xiaole Su; Bingjuan Yan; Lihua Wang; Jicheng Lv; Hong Cheng; Yipu Chen
Journal:  BMC Nephrol       Date:  2019-08-07       Impact factor: 2.388

3.  Pharmacokinetic profile of defibrotide in patients with renal impairment.

Authors:  Paola Tocchetti; Elena Tudone; Jean-Francois Marier; Thomas C Marbury; Katie Zomorodi; Mark Eller
Journal:  Drug Des Devel Ther       Date:  2016-08-16       Impact factor: 4.162

4.  Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.

Authors:  Jie Wu; Shu-Wei Duan; Xue-Feng Sun; Wen-Ge Li; Ya-Ping Wang; Wen-Hu Liu; Jian-Rong Zhang; Li-De Lun; Xue-Mei Li; Chun-Hua Zhou; Ji-Jun Li; Shu-Wen Liu; Yuan-Sheng Xie; Guang-Yan Cai; Lu Ma; Wen Huang; Hua Wu; Qiang Jia; Xiang-Mei Chen
Journal:  Chin Med J (Engl)       Date:  2016-08-20       Impact factor: 2.628
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.